Overview of Co-Prestarium

Quick Facts

Property	Description
Active ingredients	Amlodipine, Perindopril
Form	Tablet (Fixed-dose combination)
Pharmacological class	Calcium Channel Blocker (CCB) and ACE Inhibitor
Common use	Management of high blood pressure
Origin	Synthetic compound

Co-Prestarium: Definition and Core Identity

Co-Prestarium is a synthetic, prescription-only fixed-dose combination (FDC) cardiovascular medicine used for the effective management of high blood pressure, combining two distinct antihypertensive agents. Its generic designation is the combination of Amlodipine and Perindopril, which are the two primary active ingredients. This structure reflects a strategy for optimizing the long-term control of arterial hypertension in adults by using complementary mechanisms. This FDC approach is clinically recognized for supporting consistent treatment adherence when patients require multiple agents to reach their blood pressure targets.

Pharmacological Classification and Composition

The medicine is defined by its membership in two major Pharmacological Classes: it contains Amlodipine, which is categorized as a Calcium Channel Blocker (CCB), and Perindopril, which is an Angiotensin-Converting Enzyme (ACE) Inhibitor. This dual composition is prepared as an oral preparation in the form of a tablet, intended to be taken via the oral route. The formulation includes specific salt forms, such as Amlodipine besilate and Perindopril arginine or Perindopril erbumine. The pharmacological action involves blocking L-type calcium channels and inhibiting the ACE enzyme. This dual-class action provides a high degree of pharmacological complementarity for vascular regulation.

General Therapeutic Purpose and Dual Action

The general therapeutic purpose of this FDC is to achieve a potent and stable reduction in high blood pressure by utilizing a dual mechanism of action. Amlodipine acts to directly promote vasodilation by relaxing the walls of the arteries, while Perindopril modulates the Renin-Angiotensin-Aldosterone System (RAAS). The combination provides a synergistic effect that consistently reduces peripheral vascular resistance, minimizing the workload on the heart and improving overall cardiovascular function for the management of associated cardiovascular risk factors. For patients with uncontrolled high pressure, this combination is typically used to ensure sustained blood pressure control throughout the day.

What side effects are possible with Co-Prestarium?

Possible side effects and safety information

The safety profile of Co-Prestarium is established based on the regulatory documentation for its components, Amlodipine and Perindopril. Adverse reactions are classified according to frequency, reflecting their occurrence in clinical studies.

Adverse Reaction Frequencies

Classification	Examples of Documented Effects
Very Common (ge1/10)	Oedema (Ankle swelling)
Common (ge1/100 to <1/10)	Headache, Dizziness, Somnolence, Cough, Nausea, Abdominal pain, Fatigue, Muscle cramps

Adverse reactions are organized into System-Organ Classes (SOC), including Vascular disorders (Flushing, Hypotension), Nervous system disorders (Headache, Syncope), Gastrointestinal disorders (Diarrhoea, Constipation), and Respiratory disorders (Cough, Dyspnoea).

Serious Adverse Reactions and Safety Constraints

The official labeling notes specific, clinically significant events. Serious adverse reactions include Angioedema (severe swelling of the face, limbs, or tongue), Severe Hypotension, and rare cases of Hepatic Failure or Agranulocytosis.

Safety notes specify time-related patterns, stating that hypotension and dizziness are more frequently observed at the start of treatment or during dose escalation.

Safety restrictions documented in regulatory text include contraindications for use in the second and third trimesters of pregnancy, in patients with a history of Angioedema related to previous ACE inhibitor use, and in those with obstructive outflow tract pathology (e.g., severe aortic stenosis). Concomitant use with Sacubitril/Valsartan or Aliskiren (in specific patient groups) is also restricted due to safety concerns. These safety parameters define the official risk profile of the medicine.

Overdose and Emergency Response

Suspected overdosage with Co-Prestarium requires the individual to seek emergency medical attention immediately, including contacting a Poison Help line or proceeding to an emergency room at once. The primary documented clinical manifestations of overdose are a result of the combined actions of the two components.

These presentations include severe hypotension and excessive peripheral vasodilation, leading to marked and probably prolonged systemic hypotension. A severe, life-threatening manifestation of non-cardiogenic pulmonary oedema, which may have a delayed onset of 24 to 48 hours post-ingestion, has also been documented as a consequence of amlodipine overdosage.

Management for these events is defined as symptomatic and supportive treatment, as no specific antidote is known. The official regulatory protocol involves initial stabilization steps, such as an intravenous infusion of normal saline solution, and mandates continuous monitoring of vital signs, serum electrolytes, and creatinine concentrations. Specific procedures, including Angiotensin II infusion or Intravenous catecholamines, may be considered.

Haemodialysis is documented as a measure for removing the perindopril component, but not amlodipine. Regulatory authorities note that there is no specific experience of overdose documented for the fixed-dose combination itself.

Therapeutic Uses of Co-Prestarium

What Co-Prestarium Treats: Main Uses and Benefits

Co-Prestarium is a combination medicine generally used in the long-term management of specific cardiovascular conditions. The medicine is primarily used as a substitution therapy in patients already controlled on its separate components to treat essential hypertension and/or stable coronary artery disease. It provides support that helps ease the overall burden of these chronic issues.

Managing Symptomatic Discomfort in Chronic Cardiovascular Conditions

This therapeutic approach is relevant across conditions characterized by periods of persistently high blood pressure and stable forms of coronary artery disease. The medicine contributes to improved comfort during periods of heightened symptoms and supports maintaining a sense of stability. It may assist in addressing the overall symptom load related to these conditions.

“This medication is applied across domains where additional symptomatic support is needed to help patients cope more steadily with daily symptoms that interfere with functioning.”

Key Therapeutic Domains

Co-Prestarium helps manage symptoms related to conditions that present with systemic imbalance and heightened physiological activity. It is commonly used when symptoms intensify and supportive relief is needed to maintain functional stability.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Eligibility and Restrictions for Use

Who can and cannot use Co-Prestarium?

The population eligibility for the fixed-dose combination of Perindopril and Amlodipine is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated groups.

Approved and Restricted Use

Category	Eligibility Status	Conditions
Adults	Approved	Used as substitution therapy for adults already controlled on the separate components.
Renal Function	Not Suitable	Fixed-dose combination is not suitable for patients with Creatinine Clearance (Clcr) less than 60 ml/min; individual component titration is required.
Age (Pediatric)	Not Established	Should not be used in children and adolescents (under 18 years) as efficacy and safety have not been established.
Pregnancy	Not Recommended	Use is not recommended during the first trimester.
Lactation	Not Recommended	Use is not recommended during breastfeeding.

Absolute Contraindications

Co-Prestarium must not be used in patients with a history of angioedema related to any ACE inhibitor or in those with hereditary or idiopathic angioedema. It is contraindicated in women during the second and third trimesters of pregnancy. Further contraindications include hypersensitivity to either Perindopril (or any ACE inhibitor) or Amlodipine (or any dihydropyridine). Use is also prohibited in patients with severe, unstable cardiovascular conditions like severe hypotension, cardiogenic shock, or aortic stenosis. Concomitant use with sacubitril/valsartan is contraindicated, as is the use with aliskiren in patients with diabetes or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific restrictions for co-administering Co-Prestarium, which contains Amlodipine and Perindopril, with other substances. The combination of Sacubitril/Valsartan is strictly contraindicated, requiring a mandatory 36-hour separation period when initiating or stopping Perindopril to avoid the risk of angioedema. Aliskiren is also contraindicated in patients with diabetes or impaired renal function due to heightened risk of hyperkalemia and renal deterioration.

Pharmacokinetic and Pharmacodynamic Effects

Co-administration with strong or moderate CYP3A4 Inhibitors (e.g., azole antifungals) may significantly increase the exposure of the Amlodipine component. Conversely, strong CYP3A4 Inducers like St. John's wort (Hypericum perforatum) may reduce Amlodipine plasma concentrations. Concomitant use with Simvastatin results in a documented 77% increase in Simvastatin exposure. The risk of hyperkalemia is increased with Potassium-Elevating Agents (e.g., potassium-sparing diuretics or potassium supplements) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Grapefruit or Grapefruit juice co-administration is not recommended, as it may increase Amlodipine's bioavailability, potentially resulting in enhanced hypotensive effects.

Mechanism of Action

Co-Prestarium is a fixed-dose combination containing perindopril and indapamide, which modulate distinct physiological systems.

Perindopril, a prodrug, is hydrolyzed in vivo to its active metabolite, perindoprilat. Perindoprilat acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), also known as kininase II. By binding to the ACE active site, it prevents the enzymatic conversion of angiotensin I (ATI) to the vasoconstrictor angiotensin II (ATII). This molecular action reduces circulating ATII levels, leading to decreased stimulation of the AT1 receptor on vascular smooth muscle, thus causing vasodilation. Additionally, ACE inhibition impedes the degradation of bradykinin, a potent vasodilator, contributing to augmented NO and prostaglandin production, which further promotes vasodilation. The resulting intracellular cascade involves reduced smooth muscle contraction.

Indapamide is a thiazide-like diuretic that targets the kidney's cortical diluting segment of the distal convoluted tubule. It functions as an inhibitor of the Na^+/ Cl^- cotransporter on the luminal membrane, blocking the reabsorption of sodium and chloride ions. This molecular inhibition leads to an osmotic shift that increases the excretion of water, sodium, and chloride into the urine, resulting in a systemic decrease in extracellular fluid volume. Indapamide also exerts a direct vasomodulatory effect by reducing vascular reactivity to pressor amines via altered transmembrane ion transport in arterial smooth muscle cells. The combined actions yield reduced total peripheral resistance and diminished circulating blood volume.

Dosage and Administration Information

How to Use Co-Prestarium

Co-Prestarium is a fixed-dose combination (FDC) medicine administered as an oral tablet and is utilized exclusively as substitution therapy. This usage principle means the medicine is intended for patients whose blood pressure is already adequately controlled by taking the separate components, Amlodipine and Perindopril, at the same corresponding dose level.

Administration Protocol

The standard protocol mandates that the tablet be taken once daily. To support predictable absorption, administration should occur before a meal, specifically before breakfast. The tablet must be swallowed whole with a glass of water and must not be crushed or chewed.

Usage Constraint	Detail
Route & Frequency	Oral, once daily
Dose Initiation	Must be preceded by dose stabilization on separate components
Timing	Before breakfast
Handling	Swallow whole; do not crush

Procedural Adjustments and Constraints

The fixed-dose nature of the tablet imposes a significant procedural constraint: the dose of the two components cannot be individually adjusted. Consequently, any necessary dose adjustment or titration must be completed using the individual, separate medications before switching a patient to a different strength of the FDC tablet.

Additionally, caution and potential dosage modification are required for certain populations. Specific instructions exist for older adults based on renal function, and dose adjustments are explicitly required for patients with renal impairment (guided by creatinine clearance) and administered with caution in cases of hepatic impairment. If a dose is missed, patients should take the next scheduled dose at the usual time without attempting to take a double dose to compensate.

Recent Clinical Evidence

Co-Prestarium: Overview of Clinical Evidence

Evidence for use in Essential Hypertension

Large-scale Randomized Controlled Trials (RCTs) were evaluated in adults with hypertension, including those with multiple cardiovascular risk factors. These trials research examined measurements of Blood Pressure (BP) reduction and the incidence of major events like stroke. Studies comparing the amlodipine-based regimen to other control regimens research describes patterns related to major cardiovascular events and all-cause mortality over the study period. Observational studies of the specific fixed-dose combination (FDC) tablet data show patterns related to achieving BP goals and patient persistence. The primary event data, however, relies on a free combination strategy rather than the FDC tablet itself.

Evidence for use in Stable Coronary Artery Disease

This research base was studied for its potential role in patients with stable coronary artery disease (CAD). Studies explored the effect of the Perindopril component alone, which was evaluated in large RCTs, and also research examined the combination’s influence on intermediate markers like arterial health. Trials focusing on the perindopril component alone data show patterns related to long-term outcomes related to major events and total mortality. The established evidence for these outcomes is derived from trials focusing on the individual Perindopril component, leading to a lack of dedicated, long-term outcome trials for the FDC in a pure CAD population.

Research Duration and Gaps

Follow-up durations in major trials typically were limited to around five years, although some extended observation periods was observed in up to 21 years. Research was conducted in high-risk patient subgroups, such as older adults and those with diabetes. However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes regarding the specific FDC tablet, and data for pediatric populations remain insufficient because safety and efficacy are not fully established in children.

Key Studies & References

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Co-Prestarium (FAQ)

Q: How long does the effect of one tablet of Co-Prestarium last?

The official product information specifies that this medicine is intended to be taken once daily. This administration schedule reflects the required interval between doses. This means the dose is intended to provide the pharmacological effect necessary to regulate blood pressure over 24 hours.

Q: What is the difference between an ACE inhibitor and a diuretic like in Co-Prestarium?

Co-Prestarium contains two types of medicine that work differently to help manage high blood pressure. The ACE inhibitor component (perindopril) acts on the enzyme that regulates blood pressure and is described as promoting vasodilation. The diuretic component works on the kidneys to increase the excretion of water and salt, which relates to a decrease in extracellular fluid volume.

Q: Can Co-Prestarium cause a dry cough, and how long does it usually last?

A dry cough is a common side effect reported in official documents, often associated with the ACE inhibitor component (perindopril). However, regulatory information does not specify how long this cough is expected to last. The appearance of any new side effect should always be reviewed with a healthcare professional.

Q: Can Co-Prestarium impact liver enzyme levels?

Official regulatory data reports that temporary (transient) increases in liver enzyme levels have been known to occur with the use of the drug's components. This information is included in the official safety documents.

Q: Is Co-Prestarium okay for people with diabetes?

Regulatory documentation notes that research has included patient subgroups with conditions like diabetes. Furthermore, the official product information lists specific contraindications (reasons not to use the medicine) regarding co-administration with other drugs, such as Aliskiren, for patients who have diabetes or kidney impairment.

Q: Are there different strengths of Co-Prestarium, and what do the numbers mean?

Yes, Co-Prestarium is available in multiple fixed-dose strengths. The numbers in the strength (e.g., 5 mg/5 mg) specify the exact amount in milligrams ( mg) of the two active ingredients present in that tablet. The first number refers to the perindopril dose, and the second refers to the amlodipine dose.

Q: What is 'orthostatic hypotension' as it relates to Co-Prestarium?

Orthostatic hypotension is a clinical term for a sudden drop in blood pressure experienced when moving from sitting or lying down to a standing position. Regulatory documents note that side effects like dizziness and general low blood pressure (hypotension) are commonly seen. This effect is observed particularly when treatment is first started or the dose is changed.

Q: Is it safe to drink alcohol while taking Co-Prestarium?

Official product information includes a warning about the combination of this medicine and alcohol. The documented interaction suggests that alcohol may enhance the hypotensive effect of the medicine. This could potentially result in increased dizziness or light-headedness.

Q: What is the official dosage range described in the drug's package insert?

Regulatory documents define the available doses through the fixed-dose strengths in which the tablets are manufactured. These strengths represent different combinations of the two active ingredients. The range typically extends from the lowest fixed-dose combination (e.g., 5 mg/5 mg for the active ingredients) up to the highest approved combination (e.g., 10 mg/10 mg).

Q: Does Co-Prestarium have a generic version available?

Yes, the active ingredients in Co-Prestarium, perindopril and amlodipine, are available in generic formulations. These generic versions contain the same active compounds but may be marketed by different companies and under different names.

Q: Do I need to have regular blood tests while on Co-Prestarium?

Official product warnings note that monitoring of certain blood parameters, particularly potassium levels and kidney function (creatinine), is a recommended precaution. The need for monitoring relates to the known pharmacological properties of the drug's components.

Q: Does Co-Prestarium affect blood sugar levels?

Regulatory documents indicate that the diuretic component of the medicine has the potential to affect glucose control. Warnings mention that this component should be considered for individuals who have diabetes.

Q: Do official documents mention any mental health side effects, like depression, from Co-Prestarium?

Official lists of side effects include potential effects on the nervous system and mood, such as sleep disorders or general mood changes. However, a specific, consistent link to clinical depression is not generally listed as a common effect in regulatory summaries.

Q: What is the shelf life of Co-Prestarium tablets?

Official regulatory documents specify the product's shelf life, which is the period during which the medicine is expected to remain stable. This time frame is typically set at up to 3 years from the date of manufacture, provided the product is stored according to the specified instructions.

Q: What is the significance of the tablet's color or shape?

Regulatory documents include a detailed description of the tablet's appearance, including its shape, color, and any identifying marks or engravings. This information is provided to help ensure that the specific medicine and dose can be correctly identified.

Q: Is a metallic taste in the mouth a reported side effect of Co-Prestarium?

Official product information lists taste disturbance (known as dysgeusia) as a possible side effect. This involves an altered or impaired sense of taste, which for some users of ACE inhibitors, can be described as a metallic or unusual flavor. This condition is documented as an adverse reaction.

Q: Can Co-Prestarium cause sensitivity to the sun?

Regulatory warnings indicate a potential for photosensitivity due to the diuretic component of the medicine. This means that the skin may have an exaggerated reaction, such as a rash or sunburn, when exposed to sunlight or other sources of ultraviolet (UV) light.

Q: How is the medicine eliminated from the body?

According to pharmacokinetic data, the components of the medicine are processed and eliminated by the body through different primary routes. The perindopril part is mainly removed via the kidneys into the urine, while the amlodipine part is primarily metabolized by the liver before being excreted.

Q: Is Co-Prestarium a type of water pill?

Co-Prestarium is a combination medicine that includes a component belonging to the pharmacological class known as a diuretic. This class is frequently referred to by the public as a 'water pill' because its purpose is to increase the excretion of water and salt from the body.

Q: What are the main pharmacological classes that Co-Prestarium belongs to?

The medicine combines two major types of blood pressure medication, and its dual classification is established in official regulatory documents. It contains a Calcium Channel Blocker (CCB) and an Angiotensin-Converting Enzyme (ACE) Inhibitor.

How should Co-Prestarium be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Co-Prestarium — Official Regulatory Information

Detail	Official Regulatory Requirement
Labeled storage temperature requirements	Store at a temperature not exceeding 30 C
Light/moisture protection requirements	Must be kept protected from moisture and stored in the original package
Handling requirements	Do not freeze the medicinal product
Child-protection storage requirements	Keep the medicine out of the sight and reach of children
Disposal instructions (as documented in government sources)	No special requirements for disposal of unused product; must not be disposed of via wastewater or household waste

The official documents define the storage profile through explicit constraints on temperature and environment, requiring storage below 30 C and protecting the product from moisture by keeping it in the original package. These conditions maintain the labeled stability of the drug. The label also requires the product to be kept out of the reach of children, and expired portions must be discarded according to local regulations for pharmaceutical waste, not through conventional residential disposal methods.

Co-Prestarium